Definium (DFTX) CMO Daniel Karlin Sells 10,853 Shares

What Happened
Daniel Karlin, Chief Medical Officer and a member of the board of Definium Therapeutics (DFTX), disposed of 10,853 common shares on September 25, 2026. The shares were sold at a weighted average price of $36.57 per share, for total proceeds of approximately $396,894. This transaction was a sale (routine sell-to-cover) to satisfy tax-withholding obligations related to the settlement of vested restricted stock units.

Key Details

• Transaction date: September 25, 2026; Form 4 filed September 29, 2026 (timely filing).
• Transaction type: Sale (S) — 10,853 shares sold.
• Reported price: Weighted average $36.57; per-footnote range $36.24–$36.98 across multiple trades.
• Total value reported: ~$396,894.
• Shares owned after the transaction: Not disclosed in this Form 4.
• Footnotes:
  • F1 — Shares sold to satisfy withholding tax on vested RSUs pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted June 15, 2022.
  • F2 — The $36.57 is a weighted average; the filer can provide the number of shares sold at each price within the $36.24–$36.98 range upon request.

Context
Sell-to-cover transactions are common when RSUs vest and taxes are withheld; they are typically administrative and do not necessarily signal the insider’s view on the company’s prospects. The sale was executed under a pre-established Rule 10b5-1 plan, which often specifies timing and amounts for such transactions.